MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Envista Holdings Corporation Revenue 2011-2026 | NVST
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Envista Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.72 B | 2.51 B | 2.57 B | 2.57 B | 2.51 B | 1.93 B | 2.75 B | 2.84 B | 2.81 B | 2.79 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.84 B | 1.93 B | 2.6 B |
Quarterly Revenue Envista Holdings Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 706 M | 670 M | 682 M | 617 M | - | 601 M | 633 M | 624 M | - | 631 M | 662 M | 627 M | - | 631 M | 646 M | 631 M | 652 M | 607 M | 637 M | 613 M | 616 M | 547 M | 309 M | 456 M | 720 M | 659 M | 712 M | 660 M | 759 M | 680 M | 733 M | 673 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 759 M | 309 M | 634 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 62.02 | - | $ 12.3 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Glaukos Corporation
GKOS
|
507 M | $ 121.69 | - | $ 6.96 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
10.4 B | $ 66.58 | - | $ 40.4 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 418.82 | - | $ 149 B | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 134.93 | 3.38 % | $ 3.32 B | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 107.35 | - | $ 3.44 B | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 4.14 | - | $ 191 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 93.56 | 2.1 % | $ 2.12 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 178.9 | - | $ 9.54 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.96 | - | $ 89.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
12.8 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.43 | - | $ 35.3 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
32 M | $ 9.94 | - | $ 84.3 K | USA |
 |
Haemonetics Corporation
HAE
|
1.33 B | $ 69.85 | - | $ 3.3 B | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
STERIS plc
STE
|
5.94 B | $ 212.24 | -0.02 % | $ 20.8 B | USA |
 |
STAAR Surgical Company
STAA
|
239 M | $ 29.86 | - | $ 1.48 B | USA |
 |
InfuSystem Holdings
INFU
|
143 M | $ 9.12 | - | $ 188 M | USA |
 |
Teleflex Incorporated
TFX
|
569 M | $ 132.11 | - | $ 5.9 B | USA |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 63.04 | - | $ 3.73 B | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 67.99 | 3.75 % | $ 220 M | USA |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 317.32 | - | $ 22.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 9.88 | - | $ 1.97 B | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 26.94 | - | $ 1.82 B | USA |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.66 | -0.02 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
66.6 M | $ 67.0 | - | $ 220 M | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
96.2 M | $ 27.09 | -0.59 % | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.88 | - | $ 171 M | USA |
 |
Baxter International
BAX
|
11.2 B | $ 19.35 | - | $ 9.93 B | USA |
 |
ResMed
RMD
|
3.58 B | $ 194.32 | - | $ 28.4 B | USA |
 |
AtriCure
ATRC
|
535 M | $ 27.27 | - | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
86.6 M | $ 6.48 | -0.31 % | $ 288 M | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 12.03 | - | $ 491 M | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 149.56 | - | $ 43 B | USA |
 |
Nephros
NEPH
|
18.8 M | $ 3.59 | - | $ 38.1 M | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 4.17 | 5.57 % | $ 306 M | USA |
 |
Repligen Corporation
RGEN
|
738 M | $ 126.55 | - | $ 7.12 M | USA |